Pulmonary embolism (PE) presents with a variety of nonspecific symptoms. Confirmation of diagnosis involves clinical risk scores, scanning techniques, and laboratory tests. Treatment choice is guided by the risks and benefits of each strategy. New techniques and medications have been developed during the past few years. It is recommended that high-risk patients with PEs receive thrombolytic therapy or thrombectomy. Patients with less severe presentations are treated with anticoagulants, traditionally with parenteral heparins in the acute phase of treatment, transitioning to oral vitamin K antagonists (VKAs). The limitations of these agents and the introduction of non-VKA oral anticoagulants challenge this paradigm. This session will focus on the varying methodologies for prevention, management, and novel ways to remove the large pulmonary clot burden safely.
- Provider:Society of Critical Care Medicine
- Activity Link: https://congress2024.sccm.org/aaStatic.asp?SFP=VFJVUUtHWFdAMTU3NjlAQ29uZ3Jlc3MgRGlnaXRhbA
- Start Date: 2024-01-21 06:00:00
- End Date: 2024-01-21 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- MOC Credit Details: ABS - 1.25 Point; Credit Type(s): Accredited CME (ABS)
ABA - 1.25 Point; Credit Type(s): Lifelong Learning (ABA)
ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
ABP - 1.25 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Critical Care Medicine, Pediatric Critical Care Medicine, Surgical Critical Care